In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120
Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica
Psychedelic medicines specialist MindMed has said that its LSD-based treatment MM-120 has shown efficacy in a proof-of-concept study involving patients with generalised an
Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.
It’s no secret that 2023 has been a year for a shift in thinking when it comes to psychedelics, in particular as pertains to their use for hard-to-treat or treatment resistant mental health
Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.